<?xml version="1.0" encoding="UTF-8"?>
<p>Plasma from patients that have overcome COVID-19 infection, namely convalescent plasma, is a treatment with considerable historical background in other diseases, but still explorative in the context of SARS-CoV-2. In a pandemic, convalescent plasma could provide an easily accessible source of antiviral antibodies. Indeed, fresh frozen plasma (FFP) is an established treatment in many clinical indications with a well-known safety profile. The present article summarizes available evidence about convalescent plasma in COVID-19, registered trials, and guidance from authorities, providing a critical overview of published studies and perspectives.</p>
